Joshua Reed
2020 - Aldeyra Therapeutics
In 2020, Joshua Reed earned a total compensation of $1.7M as Chief Financial Officer at Aldeyra Therapeutics, a 23% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $152,857 |
---|---|
Option Awards | $621,962 |
Salary | $382,143 |
Stock Awards | $520,532 |
Other | $11,400 |
Total | $1,688,894 |
Reed received $622K in option awards, accounting for 37% of the total pay in 2020.
Reed also received $152.9K in non-equity incentive plan, $382.1K in salary, $520.5K in stock awards and $11.4K in other compensation.
Rankings
In 2020, Joshua Reed's compensation ranked 6,314th out of 13,090 executives tracked by ExecPay. In other words, Reed earned more than 51.8% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 6,314 | 52nd |
Manufacturing | 2,602 | 54th |
Chemicals And Allied Products | 1,048 | 54th |
Drugs | 905 | 54th |
Pharmaceutical Preparations | 676 | 54th |
Reed's colleagues
We found one more compensation record of an executive who worked with Joshua Reed at Aldeyra Therapeutics in 2020.
2020
Todd Brady
Aldeyra Therapeutics